Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Adiponectin is a secretory protein predominantly expressed by adipocytes and released at a high rate into circulation. The ease with which the levels of adiponectin can be measured owing to its high abundance, small diurnal variation and high stability in plasma have made it a popular target for measurements in many clinical studies. It has emerged as a valuable biomarker for insulin sensitivity, cardiovascular risk and inflammation. However, adiponectin levels have been measured in many additional disease states. Preclinical studies not only have implicated adiponectin as an outstanding biomarker but also have demonstrated direct cardio-protective and insulin-sensitizing properties to be associated with the protein. Adiponectin might, therefore, be a viable protein therapeutic that could be supplied in a recombinant form in the context of type 2 diabetes and cardiovascular disease. However, the high abundance, complex tertiary and quaternary structure and rapid turnover might make chronic administration of the protein rather challenging.

Original languageEnglish (US)
Pages (from-to)234-239
Number of pages6
JournalTrends in Pharmacological Sciences
Volume30
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Adiponectin
Health
Pharmaceutical Preparations
Biomarkers
Proteins
Insulin
Medical problems
Adipocytes
Type 2 Diabetes Mellitus
Insulin Resistance
Cardiovascular Diseases
Inflammation
Plasmas

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

@article{0bc487fee1544cdd820e7c3000147ad2,
title = "Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies",
abstract = "Adiponectin is a secretory protein predominantly expressed by adipocytes and released at a high rate into circulation. The ease with which the levels of adiponectin can be measured owing to its high abundance, small diurnal variation and high stability in plasma have made it a popular target for measurements in many clinical studies. It has emerged as a valuable biomarker for insulin sensitivity, cardiovascular risk and inflammation. However, adiponectin levels have been measured in many additional disease states. Preclinical studies not only have implicated adiponectin as an outstanding biomarker but also have demonstrated direct cardio-protective and insulin-sensitizing properties to be associated with the protein. Adiponectin might, therefore, be a viable protein therapeutic that could be supplied in a recombinant form in the context of type 2 diabetes and cardiovascular disease. However, the high abundance, complex tertiary and quaternary structure and rapid turnover might make chronic administration of the protein rather challenging.",
author = "Shoba Shetty and Kusminski, {Christine M.} and Scherer, {Philipp E.}",
year = "2009",
month = "5",
doi = "10.1016/j.tips.2009.02.004",
language = "English (US)",
volume = "30",
pages = "234--239",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Adiponectin in health and disease

T2 - evaluation of adiponectin-targeted drug development strategies

AU - Shetty, Shoba

AU - Kusminski, Christine M.

AU - Scherer, Philipp E.

PY - 2009/5

Y1 - 2009/5

N2 - Adiponectin is a secretory protein predominantly expressed by adipocytes and released at a high rate into circulation. The ease with which the levels of adiponectin can be measured owing to its high abundance, small diurnal variation and high stability in plasma have made it a popular target for measurements in many clinical studies. It has emerged as a valuable biomarker for insulin sensitivity, cardiovascular risk and inflammation. However, adiponectin levels have been measured in many additional disease states. Preclinical studies not only have implicated adiponectin as an outstanding biomarker but also have demonstrated direct cardio-protective and insulin-sensitizing properties to be associated with the protein. Adiponectin might, therefore, be a viable protein therapeutic that could be supplied in a recombinant form in the context of type 2 diabetes and cardiovascular disease. However, the high abundance, complex tertiary and quaternary structure and rapid turnover might make chronic administration of the protein rather challenging.

AB - Adiponectin is a secretory protein predominantly expressed by adipocytes and released at a high rate into circulation. The ease with which the levels of adiponectin can be measured owing to its high abundance, small diurnal variation and high stability in plasma have made it a popular target for measurements in many clinical studies. It has emerged as a valuable biomarker for insulin sensitivity, cardiovascular risk and inflammation. However, adiponectin levels have been measured in many additional disease states. Preclinical studies not only have implicated adiponectin as an outstanding biomarker but also have demonstrated direct cardio-protective and insulin-sensitizing properties to be associated with the protein. Adiponectin might, therefore, be a viable protein therapeutic that could be supplied in a recombinant form in the context of type 2 diabetes and cardiovascular disease. However, the high abundance, complex tertiary and quaternary structure and rapid turnover might make chronic administration of the protein rather challenging.

UR - http://www.scopus.com/inward/record.url?scp=65349162789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349162789&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2009.02.004

DO - 10.1016/j.tips.2009.02.004

M3 - Article

C2 - 19359049

AN - SCOPUS:65349162789

VL - 30

SP - 234

EP - 239

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 5

ER -